Management of Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases

Publication Date: May 31, 2022
Last Updated: May 31, 2022

Local Therapy

Brain Metastases

Recommendation 1.0

Multidisciplinary collaboration to formulate treatment and care plans and disease management for patients with HER2-positive metastatic breast cancer should be the standard of care. ( EB , B , I , S )
615

Systemic Therapy

Recommendation 7.1

The combination of tucatinib, and capecitabine and trastuzumab may be offered to patients with HER2 positive metastatic breast cancer who have brain metastases without symptomatic mass effect and whose disease has progressed on at least one previous HER2-directed therapy for metastatic disease. If these agents are used, local therapy may be delayed until there is evidence of intracranial progression. ( EB , , L , W )
615

Overview

Title

Management of Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases

Authoring Organization